Our own research focuses on the generation of patient-specific and CRISPR-engineered iPSCs and their applications in cardiac disease modeling, tissue engineering, high-content drug screening and CRISPR/Cas-based gene therapy. By combining iPSC technology with further state-of-the-art approaches, we aim to deeply investigate the development, function and pathophysiology of cardiomyocytes on molecular, omics-based, functional as well as pharmacological level. The spanning goal of our research is the identification of novel pathophysiological mechanisms in cardiomyopathy/heart failure and the development of preventive and/or curative therapies.